SAM
FOLD

Silvercrest Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Silvercrest Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-945,628
Closed -$13.5M – 857
2025
Q4 		$13.5M Buy
945,628
+1,173
+0.1% +$11.5K 0.09% 274
2025
Q3 		$7.44M Sell
944,455
-23,776
-2% -$169K 0.05% 365
2025
Q2 		$5.55M Buy
968,231
+434,520
+81% +$2.8M 0.04% 417
2025
Q1 		$4.36M Sell
533,711
-1,544
-0.3% -$14.3K 0.03% 431
2024
Q4 		$5.04M Sell
535,255
-2,384
-0.4% -$24.8K 0.03% 422
2024
Q3 		$5.74M Sell
537,639
-3,099
-0.6% -$33.8K 0.04% 363
2024
Q2 		$5.36M Buy
540,738
+165,780
+44% +$1.7M 0.04% 388
2024
Q1 		$4.42M Buy
374,958
+16,033
+4% +$205K 0.03% 411
2023
Q4 		$5.09M Sell
358,925
-74
-0% -$840 0.04% 370
2023
Q3 		$4.37M Buy
358,999
+78,615
+28% +$1.01M 0.03% 382
2023
Q2 		$3.52M Buy
280,384
+41,488
+17% +$492K 0.03% 418
2023
Q1 		$2.65M Sell
238,896
-189
-0.1% -$2.33K 0.02% 439
2022
Q4 		$2.92M Sell
239,085
-179,838
-43% -$2.02M 0.02% 419
2022
Q3 		$4.37M Sell
418,923
-10,707
-2% -$119K 0.04% 349
2022
Q2 		$4.61M Sell
429,630
-21,728
-5% -$179K 0.04% 357
2022
Q1 		$4.27M Buy
451,358
+4,899
+1% +$45.9K 0.03% 398
2021
Q4 		$5.16M Buy
446,459
+1,566
+0.4% +$17.5K 0.03% 370
2021
Q3 		$4.25M Sell
444,893
-8,262
-2% -$84.5K 0.03% 404
2021
Q2 		$4.37M Buy
453,155
+147,980
+48% +$1.44M 0.03% 412
2021
Q1 		$3.02M Buy
305,175
+131,253
+75% +$2.03M 0.02% 442
2020
Q4 		$4.02M Sell
173,922
-27,754
-14% -$568K 0.03% 389
2020
Q3 		$2.85M Sell
201,676
-3,619
-2% -$52.7K 0.02% 416
2020
Q2 		$3.1M Buy
+205,295
New +$2.5M 0.03% 400

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Silvercrest Asset Management's FOLD Position: Q1 2026 in Review

Silvercrest Asset Management sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 945,628 shares — an estimated $13.5M sold.

Silvercrest Asset Management first reported a position in FOLD in Q2 2020 and held it in 23 quarters. The position peaked at $13.5M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Silvercrest Asset Management reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Silvercrest Asset Management sold 945,628 Amicus Therapeutics shares in Q1 2026, an estimated $13.5M.
  • Silvercrest Asset Management first reported a position in Amicus Therapeutics in Q2 2020 and held it in 23 quarters.
  • Silvercrest Asset Management's Amicus Therapeutics position peaked at $13.5M in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Silvercrest Asset Management's 13F filing for Q1 2026, filed 15 May 2026.